Blood test breakthrough could simplify treatment for debilitating nerve diseases
NCT ID NCT04356781
Summary
This study aimed to see if simple blood tests taken right after starting a standard IVIg treatment could predict the best long-term dose for patients with CIDP or MMN. These are chronic nerve disorders that cause weakness and require ongoing IVIg treatment. Researchers followed 20 patients to check if early changes in a blood protein (IgG) could help doctors find the lowest effective dose faster, reducing side effects and costs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Walton Centre NHS Foundation Trust
Liverpool, Merseyside, L9 7LJ, United Kingdom
Conditions
Explore the condition pages connected to this study.